福安药业：预计2025年上半年净利润同比下降39.95%-53.81%

Core Viewpoint - The company Fu'an Pharmaceutical (300194) expects a significant decline in net profit for the first half of 2025, primarily due to price reductions in its main products as a result of nationwide centralized procurement [1] Financial Performance - The projected net profit attributable to shareholders for the period from January 1, 2025, to June 30, 2025, is estimated to be between 100 million to 130 million yuan, representing a year-on-year decrease of 39.95% to 53.81% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 91 million to 121 million yuan, reflecting a year-on-year decline of 40.50% to 55.25% [1] Market Conditions - The decline in performance is primarily attributed to the implementation of centralized procurement across the country, which has led to a substantial decrease in the sales prices of the company's main products [1]